After ~16 years as Clinical Director within NHGRI's Intramural Research Program, Bill Gahl, M.D., Ph.D., stepped down from this important leadership position at the end of 2018. Bill has developed an outstanding track record as both a physician and a scientist. Although he has stepped down as Clinical Director, he will remain at NHGRI to focus on his research program.
Bill earned both an M.D. and a Ph.D. from the University of Wisconsin, after which he trained in pediatrics at the same institution. He then came to NIH for successive fellowships in clinical genetics and clinical biochemical genetics within the NIH's Inter-Institute Medical Genetics Training Program, which he then directed from 1989 to 1994. During his lengthy research career, Bill has focused on the natural history of rare metabolic disorders and the discovery of new genetic diseases. He has made seminal discoveries about inborn errors of metabolism (including the establishment of the field of lysosomal membrane transport) by discovering the basic defects in cystinosis, Salla disease, and infantile free sialic acid storage disease. He brought the cystine-depleting agent cysteamine, a life-saving compound, to New Drug Approval in 1994 by his testimony before an FDA panel. Bill has become the world's expert on cystinosis, disorders of sialic acid metabolism, Hermansky-Pudlak syndrome, and alkaptonuria.
One of Bill's signature professional achievements was the founding of the NIH Undiagnosed Diseases Program (UDP), announced in May 2008 by then-NIH Director Dr. Elias Zerhouni. The UDP aims to provide answers to patients with mysterious medical conditions that have long eluded diagnosis. This trans-NIH initiative, which has brought distinction to the NIH Intramural Research Program and the NIH Clinical Center, focuses on the most puzzling medical cases from around the world. As the founding Director of the UDP, Bill brokered a unique combination of medical and scientific resources to make genetic discoveries and further the research of undiagnosed diseases. Key to the UDP's successes to date has been Bill's ability to recruit both outstanding NIH clinicians as well as genomic experts and technologies (including genome sequencing) to the program. As one of his UDP highlights, Bill fondly recalls the discovery of the program's first new disease - Arterial Calcification due to Deficiency of CD73; this work was published in the New England Journal of Medicine in 2011. Building on the early successes of the UDP, NIH expanded the program to form a national Undiagnosed Diseases Network (UDN) in 2012. Bill worked internationally to expand that effort to the Undiagnosed Diseases Network International (UDNI), which now involves numerous clinical researchers in over a dozen countries. Without Bill's leadership and vision, these undiagnosed disease efforts would have never come to fruition.
Bill's record of accomplishments is quite impressive. He has published more than 450 papers and trained 42 biochemical geneticists. He has received the Dr. Nathan Davis Award for Outstanding Government Service from the American Medical Association, the Service to America Medal in Science and the Environment in 2011, a tribute by Senator Ben Cardin in the Congressional Record on March 10, 2015, and elected into the National Academy of Medicine in October 2018. As a seminal honor, Bill was invited to deliver the 2018 NIH Clinical Center Astute Clinician Lecture, which he presented on November 7, 2018. He has appeared on TV multiple times: 60 Minutes, CNN, FOX, PBS, Discovery Channel; in addition, he and the UDP/UDN have been featured in dozens of prominent news features in the printed and electronic press (e.g., see next story).
Known for his relentless repertoire of jokes, Bill has a large personality that is known well beyond NHGRI. His intellectual and community contributions to NHGRI and NIH have been nothing short of spectacular to date and will now continue in the next phase of his career. In the near future, a search will be launched for a new NHGRI Clinical Director; in the interim, Dr. Dan Kastner, Director of NHGRI's Division of Intramural Research, is serving as Acting Clinical Director. For more information on NHGRI's Office of the Clinical Director, see genome.gov/10001531/office-of-the-clinical-director//.